Surgical Chips Market to grow at a CAGR of 7.57% during 2025 to 2035; Driven by Increasing Adoption of Advanced Surgical Technologies and Rising Demand for Minimally Invasive Procedures

Surgical Chips Market Regional Analysis

Surgical Chips Market Size was estimated at 4.84 USD Billion in 2024. The Surgical Chips industry is projected to grow from 5.206 USD Billion in 2025 to 10.8 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 7.57% during the forecast period 2025 - 2035.

The global surgical chips market is growing with the rapid pace; mainly due to the increasing penetration of technology in healthcare sector, and rising awareness about the use of surgical chips for patient tracking, medical records management, and healthcare quality control. According to a recent study report published by the Market Research Future, the global surgical chips market is booming, and expected to gain prominence over the forecast period growing rapidly .

Competitive Analysis

Well established players incorporate acquisition, collaboration, partnership, expansion, and product launch in order to gain competitive advantage in this market and to maintain their market position.

Abbott (U.S.), Agilent Technologies, Inc. (U.S.) Perkin Elmer, Inc. (U.S.) Fluidigm Corporation (U.S.) Illumina, Inc. (U.S.) General Electric Company (U.K), Bio-Rad Laboratories Inc. (U.S.)  Cepheid (U.S.),  Thermo Fisher Scientific, Inc. (U.S.),  F. Hoffmann-La Roche Ltd (Switzerland) are some of the prominent players at the forefront of competition in the global surgical chips market and are profiled in MRFR Analysis. 

Boston Scientific Corporation

Boston Scientific Corporation, headquartered in the U.S., is a global manufacturer and developer of medical devices. The company has adopted various strategies to sustain in the competitive market, for instance, new products launch.

PROMUS Element Plus Stent, REBEL Stent System, SYNERGY Stent are some of the major products of the company.

Abbott

Abbott, headquartered in U.S., is one of the leading healthcare company. In June 2016, FDA has approved the Absorb bioresorbable Stent for heart. This stents is completely dissolve in the body and used in the treatment of heart complications. Company’s Esprit bioresorbable vascular scaffold is under clinical trials.Hoffmann-La Roche AG

Headquartered in Basel, Switzerland; F. Hoffmann-La Roche AG is a company manufacturing and marketing number of innovative diagnostic tests, and medicines across the globe. The company offers various products in the pharmaceutical, diagnostics and research industry.

• In February 2015, F. Hoffmann-La Roche AG announced the its collaboration with BioMed X for the development of Nanomaterial-Based Biosensors for Near-Patient Testing


• In September 2014, F. Hoffmann-La Roche AG launched Elecsys anti-Müllerian Hormone (AMH) fertility test for assessment of ovarian reserve for pregnancy

Medtronic plc.

Founded in 1949, Medtronic plc. is a global healthcare solutions company committed to improving the lives of people through their medical technologies, services, and solutions.

• October, 2016: Medtronics plc. received an approval for its suite of cardiac rhythm and heart failure devices and leads to be scanned in both 3 and 1.5 Tesla (T) magnetic resonance imaging (MRI) machines. This FDA approval will help the company to strengthen its position in MRI machines segment.


• December, 2015: Medtronic plc. and Samsung came together in an alliance to accelerate the development of digital health solutions for the millions of people suffering from chronic pain, movement disorders, incontinence, and other conditions who could benefit from neuromodulation therapy. Due to this Medtronics seeks to deliver real-time data to the patients and the physicians so they effectively find the cure for the tracked symptoms.


• In 2015: Medtronic plc. developed Stent Graft System for Endovascular Repair of Thoracoabdominal Aortic Aneurysms. Earlier company’s Resolute Drug-Eluting Stent has shown a very good performance in Diabetic Patients with Heart Disease.

General Electric Company

General Electric Company is an American multinational company headquartered in U.K.

• In March, 2017, General Electric Company acquired Monica Healthcare which is a U.K based company. This acquisition has expand GE's digital product offering and has help in improving the market.


• In June, 2016, General Electric Company launched sweat equity sensors which is a wireless skin sensors used to check vital signs and monitor the health.

Regional Analysis

America dominated the global surgical chips market owing to the presence of huge geriatric population, and increasing prevalence of chronic diseases. It consists of two major regions namely North America and South America. North America holds the major share of Americas surgical chips market due to presence of many opportunities such as increasing government support and high healthcare spending. On the other hand, South America is expected to grow at faster rate due to developing market.

Asia Pacific is the fastest growing market for surgical chips market due to large increasing demand for technologically advanced medical devices, patients’ population and growing geriatric population. Vast development of healthcare information technology, and its extensive use further fuels the market growth. According to the World Bank, in Asia, 4,511 surgeries per 1,00,000 are performed in 2012 and the number will continuously rise due to increasing prevalence of different diseases.